Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 28, 2026, 10:06 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1081–1104 of 3,545 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Infant Clear all
Completed Phase 2 Interventional Results available

Safety Study of Ivacaftor in Subjects With Cystic Fibrosis

NCT00457821
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
Ivacaftor 25 mg/75 mg, Ivacaftor 75 mg/150 mg, Ivacaftor 150 mg or 250 mg, Placebo
Drug
Lead sponsor
Vertex Pharmaceuticals Incorporated
Industry
Eligibility
18 Years and older
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
13
States / cities
Birmingham, Alabama • Palo Alto, California • Aurora, Colorado + 9 more
Source: ClinicalTrials.gov public record
Updated Oct 5, 2012 · Synced Oct 28, 2026, 10:06 AM EDT
Not yet recruiting No phase listed Observational

Pharmacokinetics of CFTR Modulators in Pregnant Individuals and in Postpartum Breastfeeding Mothers

NCT04940533
View directory record Official record
Conditions
Cystic Fibrosis, Pregnancy
Interventions
Not listed
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years and older · Female only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2027 – 2028
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Jan 20, 2026 · Synced Oct 28, 2026, 10:06 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Phase 1b/2a Randomized, Double-Blind, Placebo-controlled, Dose-escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of MEDI8897, a Monoclonal Antibody With an Extended Half-life Against Respiratory Syncytial Virus, in Healthy Preterm Infants

NCT02290340
View directory record Official record
Conditions
Respiratory Syncytial Virus
Interventions
Placebo, MEDI8897 10 mg, MEDI8897 25 mg, MEDI8897 50 mg
Drug
Lead sponsor
MedImmune LLC
Industry
Eligibility
Up to 12 Months
Enrollment
151 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
7
States / cities
Anaheim, California • Ontario, California • Syracuse, New York + 4 more
Source: ClinicalTrials.gov public record
Updated Sep 19, 2018 · Synced Oct 28, 2026, 10:06 AM EDT
Completed No phase listed Observational

Effects of Highly Active Anti-Retroviral Therapy on Cardiovascular Health in Infants of HIV-Infected Mothers

NCT00253682
View directory record Official record
Conditions
Cardiovascular Diseases, Heart Diseases, Atherosclerosis, HIV Infections, Cardiomyopathy, Hypertrophic
Interventions
Not listed
Lead sponsor
University of Miami
Other
Eligibility
Up to 2 Years
Enrollment
167 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2006
U.S. locations
5
States / cities
Miami, Florida • Chicago, Illinois • Boston, Massachusetts + 2 more
Source: ClinicalTrials.gov public record
Updated Mar 18, 2014 · Synced Oct 28, 2026, 10:06 AM EDT
Completed No phase listed Observational Results available

Long-Term Effects of Hydroxyurea in Children With Sickle Cell Anemia (The BABY HUG Follow-up Study)

NCT00890396
View directory record Official record
Conditions
Anemia, Sickle Cell
Interventions
Hydroxyurea
Drug
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
2 Years to 7 Years
Enrollment
163 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
14
States / cities
Birmingham, Alabama • Washington D.C., District of Columbia • Miami, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated Aug 20, 2020 · Synced Oct 28, 2026, 10:06 AM EDT
Terminated Phase 2 Interventional

Nasogastric/Oral Gastric Tube Placement in Infants: Comparing 2 Measurement Methods

NCT01407991
View directory record Official record
Conditions
Enteral Tube Placement
Interventions
enteral tube placement accuracy, NEM method for NG/OG tube placement
Other
Lead sponsor
Children's Hospital of Philadelphia
Other
Eligibility
Up to 6 Months
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 10, 2015 · Synced Oct 28, 2026, 10:06 AM EDT
Completed No phase listed Observational

NIRS Predict Low Cardiac Output State in Neonates and Infants in Cardiac Surgery

NCT01849120
View directory record Official record
Conditions
Congenital Heart Disease
Interventions
EQUANOX Advance 8004CB sensor
Device
Lead sponsor
Mayo Clinic
Other
Eligibility
Up to 3 Years
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Apr 14, 2017 · Synced Oct 28, 2026, 10:06 AM EDT
Active, not recruiting Not applicable Interventional

Frequent Standardized Oral Care to Improve Health Outcomes in Premature Infants in the Neonatal Intensive Care Unit

NCT05167318
View directory record Official record
Conditions
Microbial Colonization, Ventilator Associated Pneumonia
Interventions
frequent standardized oral care
Other
Lead sponsor
University of Florida
Other
Eligibility
12 Hours to 72 Hours
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated May 18, 2026 · Synced Oct 28, 2026, 10:06 AM EDT
Completed Not applicable Interventional Results available

Intensive Intervention for Toddlers With Autism (EARLY STEPS)

NCT00698997
View directory record Official record
Conditions
Autism, Autism Spectrum Disorder
Interventions
Early Start Denver Model, Standard community care
Behavioral
Lead sponsor
University of California, Davis
Other
Eligibility
12 Months to 24 Months
Enrollment
118 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Feb 17, 2020 · Synced Oct 28, 2026, 10:06 AM EDT
Withdrawn No phase listed Observational

Pulmonary Function During Prone and Supine Positioning in NICU Infants Requiring Assisted Ventilation

NCT00749762
View directory record Official record
Conditions
Pulmonary Function
Interventions
Not listed
Lead sponsor
University of Utah
Other
Eligibility
24 Hours to 6 Months
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2010
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated May 5, 2015 · Synced Oct 28, 2026, 10:06 AM EDT
Completed Not applicable Interventional

Evaluation of Prolact-Plus Human Milk Fortifier

NCT00486590
View directory record Official record
Conditions
Infant, Very Low Birth Weight
Interventions
Prolact-Plus Human Milk Fortifier
Procedure
Lead sponsor
Prolacta Bioscience
Industry
Eligibility
1 Day to 30 Days
Enrollment
105 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
4
States / cities
Gainesville, Florida • Hollywood, Florida • Miami, Florida + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 17, 2021 · Synced Oct 28, 2026, 10:06 AM EDT
Completed Phase 3 Interventional Results available

A Study Evaluating the Long-term Safety and Efficacy of VX-445 Combination Therapy

NCT03525574
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
ELX/TEZ/IVA, IVA
Drug
Lead sponsor
Vertex Pharmaceuticals Incorporated
Industry
Eligibility
12 Years and older
Enrollment
507 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
52
States / cities
Tucson, Arizona • Little Rock, Arkansas • Long Beach, California + 47 more
Source: ClinicalTrials.gov public record
Updated Sep 24, 2025 · Synced Oct 28, 2026, 10:06 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Pregnancy Registry, Infants, Serum/Milk Analysis (PRISMA)

NCT06940323
View directory record Official record
Conditions
Multiple Sclerosis, Clinically Isolated Syndrome, NMOSD, Myasthenia Gravis
Interventions
Not listed
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years to 64 Years · Female only
Enrollment
250 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2035
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Aug 11, 2026 · Synced Oct 28, 2026, 10:06 AM EDT
Completed Not applicable Interventional

Comprehensive Exercise Training Program During Hospitalization for an Acute CF Exacerbation

NCT01759342
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
Aerobic exercise, Resistance exercise, Flexibility and postural exercise, Balance exercise
Behavioral
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
6 Years to 21 Years
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Jun 30, 2015 · Synced Oct 28, 2026, 10:06 AM EDT
Active, not recruiting No phase listed Observational

A Study to Assess Maternal and Fetal Outcomes After Taking Prucalopride During Pregnancy

NCT04961840
View directory record Official record
Conditions
Constipation, Pregnancy
Interventions
No Intervention
Other
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 44 Years · Female only
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Oct 28, 2026, 10:06 AM EDT
Recruiting Not applicable Interventional

Standardized Application of Feeding Evaluations Using SMART Tool

NCT07136610
View directory record Official record
Conditions
Infant and Young Child Feeding
Interventions
SMART Tool
Behavioral
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
Up to 1 Year
Enrollment
3,500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
14
States / cities
Barrington, Illinois • Chicago, Illinois • Elgin, Illinois + 11 more
Source: ClinicalTrials.gov public record
Updated Jul 29, 2026 · Synced Oct 28, 2026, 10:06 AM EDT
Enrolling by invitation No phase listed Observational

Mycobacteriophage Treatment of Non-tuberculosis Mycobacteria

NCT06262282
View directory record Official record
Conditions
Cystic Fibrosis, Nontuberculous Mycobacterial Lung Disease, Nontuberculous Mycobacterium Infection, Mycobacterium Infections, Mycobacterium; Pulmonary
Interventions
mycobacteriophage
Biological
Lead sponsor
National Jewish Health
Other
Eligibility
6 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
18
States / cities
Birmingham, Alabama • Los Angeles, California • San Diego, California + 14 more
Source: ClinicalTrials.gov public record
Updated May 21, 2025 · Synced Oct 28, 2026, 10:06 AM EDT
Terminated Phase 3 Interventional Accepts healthy volunteers Results available

A Phase III, Double-blind Study to Assess Safety and Efficacy of an RSV Maternal Unadjuvanted Vaccine, in Pregnant Women and Infants Born to Vaccinated Mothers

NCT04605159
View directory record Official record
Conditions
Respiratory Syncytial Virus Infections
Interventions
RSV MAT, Placebo
Biological · Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 49 Years · Female only
Enrollment
11,194 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2023
U.S. locations
41
States / cities
Birmingham, Alabama • Dothan, Alabama • Mobile, Alabama + 35 more
Source: ClinicalTrials.gov public record
Updated Feb 20, 2025 · Synced Oct 28, 2026, 10:06 AM EDT
Terminated Phase 2 Interventional Results available

Losartan and Inflammation in Cystic Fibrosis

NCT03206788
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
Losartan, placebo
Drug
Lead sponsor
University of Miami
Other
Eligibility
12 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
4
States / cities
Birmingham, Alabama • Miami, Florida • Kansas City, Kansas + 1 more
Source: ClinicalTrials.gov public record
Updated Nov 27, 2020 · Synced Oct 28, 2026, 10:06 AM EDT
Completed No phase listed Observational

Study of Non-Invasive Regional Oxygen Saturations in Pediatric Patients Undergoing Cardiac Catheterization

NCT00939224
View directory record Official record
Conditions
Cardiovascular Disease
Interventions
Model 7600 Regional Oximeter System
Device
Lead sponsor
Nonin Medical, Inc
Industry
Eligibility
Up to 12 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
3
States / cities
Stanford, California • Chicago, Illinois • Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 25, 2011 · Synced Oct 28, 2026, 10:06 AM EDT
Not yet recruiting Phase 4 Interventional

Oral Antibiotic Pharmacokinetics in Young Infants

NCT07815613
View directory record Official record
Conditions
Linezolid Pharmacokinetics in Young Infants, Pharmacokinetic Analysis, Linezolid, Infant and Young Children
Interventions
Linezolid (LZD)
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
0 Days to 90 Days
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2027 – 2030
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Sep 11, 2026 · Synced Oct 28, 2026, 10:06 AM EDT
Completed Not applicable Interventional

NICU Parent Education Program

NCT02528227
View directory record Official record
Conditions
Language Development, Premature Infant, Neurodevelopmental Outcomes
Interventions
Know Your Baby Language Curriculum, Reading Aloud Language Curriculum, Sing A Long Language Curriculum, Mimicking First Sounds Language Curriculum, Language Games and Narrating Your Day Language Curriculum, Feeding Safety, Car Seat Safety, Bath Safety, Back to Sleep/SIDS prevention, Taking a Temperature and Signs of Infection, Infection Control Measures and Vaccine Information
Other
Lead sponsor
Women and Infants Hospital of Rhode Island
Other
Eligibility
23 Weeks to 32 Weeks
Enrollment
95 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2020
U.S. locations
1
States / cities
Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated May 3, 2022 · Synced Oct 28, 2026, 10:06 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Phase 1 Study to Evaluate the Relative Bioavailability of a VX-828 Tablet Formulation

NCT06861413
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
VX-828
Drug
Lead sponsor
Vertex Pharmaceuticals Incorporated
Industry
Eligibility
18 Years to 55 Years
Enrollment
68 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated Jun 4, 2025 · Synced Oct 28, 2026, 10:06 AM EDT
Completed Not applicable Interventional

Extensively Hydrolyzed Formula: Hypoallergenicity

NCT01278446
View directory record Official record
Conditions
Food Hypersensitivity
Interventions
Extensively hydrolyzed, whey protein infant formula, Extensively hydrolyzed, casein protein infant formula
Other
Lead sponsor
Société des Produits Nestlé (SPN)
Industry
Eligibility
2 Months to 12 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
14
States / cities
Little Rock, Arkansas • Huntington Beach, California • Roseville, California + 11 more
Source: ClinicalTrials.gov public record
Updated Nov 4, 2013 · Synced Oct 28, 2026, 10:06 AM EDT